ENDOMETRIAL MIXED CELL ADENOCARCINOMA
Clinical trials for ENDOMETRIAL MIXED CELL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ENDOMETRIAL MIXED CELL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for ENDOMETRIAL MIXED CELL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for aggressive uterine cancer: drug combo targets Obesity-Linked tumors
Disease control Recruiting nowThis early-stage study tests the safety of combining two drugs, atezolizumab and ONC201, for women with advanced or recurrent endometrial cancer. The trial includes both obese and non-obese participants to see how body weight affects treatment. Researchers aim to find the best do…
Matched conditions: ENDOMETRIAL MIXED CELL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 05, 2026 11:53 UTC
-
Immunotherapy double punch may beat single drug for returning uterine cancer
Disease control Recruiting nowThis study is for people with a type of recurrent endometrial cancer that has a specific DNA repair problem (dMMR). It compares a combination of two immunotherapy drugs (nivolumab and ipilimumab) against nivolumab alone to see which shrinks tumors better. About 81 participants wi…
Matched conditions: ENDOMETRIAL MIXED CELL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 26, 2026 20:02 UTC
-
Major trial aims to tame aggressive uterine cancer with targeted drug cocktails
Disease control Recruiting nowThis large, late-stage trial is testing whether adding newer, faster-to-administer targeted drugs to standard chemotherapy is better at controlling a specific, aggressive type of uterine cancer (HER2-positive). It will involve 360 patients who have recently been diagnosed and hav…
Matched conditions: ENDOMETRIAL MIXED CELL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 13, 2026 20:20 UTC